Shares of Teladoc Health (NYSE: TDOC) were a bit sickly on Monday after one of the more prominent analysts tracking the stock knocked his target price down. Truist Securities' Sandy Draper, who has closely followed the fortunes of Teladoc throughout the coronavirus pandemic, was the prognosticator shaving his price target. The change comes not long after Teladoc reported its first-quarter results.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting